The U Food and Drug Administration (FDA) has completed its review of Moderna’s investigational new drug (IND) application for Covid-19 vaccine candidate, mRNA-1273, authorising the company to conduct a Phase II study.
The protocol for Phase III study of mRNA-1273 has also been finalised. While the Phase II clinical trial is set to begin soon, the Phase III study will be conducted later this year.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
